Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.54 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313178 | 0.89 | KDM4E (0.70) | KDM4EALDH1A1POLBBRD4CTDSP1 | |
| SCHEMBL3319323 | 0.88 | KDM4E (0.71) | KDM4EALDH1A1POLBBRD4CTDSP1 | |
| SCHEMBL3313341 | 0.86 | POLB (0.80) | KDM4EALDH1A1POLBKMT2ARXRA | |
| SCHEMBL3310748 | 0.85 | KDM4E (0.70) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL3319478 | 0.85 | KDM4E (0.73) | KDM4EALDH1A1POLBBRD4CTDSP1 | |
| SCHEMBL3312894 | 0.85 | PKM (0.66) | KDM4EALDH1A1POLBKMT2AEGFR | |
| SCHEMBL3311016 | 0.83 | KDM4E (1.00) | KDM4EALDH1A1POLBKMT2AHTT | |
| SCHEMBL3318235 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL3314542 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL3312768 | 0.82 | KDM4E (0.70) | KDM4EALDH1A1POLBKMT2ARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737809-A4 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2007-10-17 | — | — | EP | claimed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | claimed |
| EP-1737809-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2007-01-03 | — | — | EP | claimed |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. | 2006-01-05 | — | — | US | claimed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7649110-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1737809-A4 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1737809-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | KDM4E 4456/4885ALDH1A1 1567/4885POLB 3170/4885 |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | KDM4E 4456/4885ALDH1A1 1567/4885POLB 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.